Skip to main content
Guttmacher Institute

Search

  • X
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
  • Contact

Highlights

  • Reproductive Health Impact Study
  • Adding It Up
  • Abortion Worldwide
  • Guttmacher-Lancet Commission
  • US policy resources
  • State policy resources
  • International Perspectives on Sexual and Reproductive Health (1975–2020)
  • Perspectives on Sexual and Reproductive Health (1969–2020)

Reports

  • Global
  • United States

Articles

  • Global research
  • US research
  • Policy analysis
  • Guttmacher Policy Review
  • Opinion

Fact Sheets

  • Global
  • United States
  • US State Laws and Policies

Tools

  • Interactive Map: US Abortion Policies and Access After Roe
  • Family Planning Investment Impact Calculator
  • Monthly Abortion Provision Study Dashboard
  • State legislation tracker
  • Public-use data sets

Global

  • Abortion
  • Contraception
  • Pregnancy
  • Teens

US

  • Abortion
  • Contraception
  • Pregnancy
  • Teens

Our Work by Geography

  • Global
  • Africa
  • Asia
  • Europe
  • Latin America & the Caribbean
  • Northern America
  • Oceania

Who We Are

  • About
  • Staff
  • Board
  • Job opportunities
  • Newsletter
  • History
  • Contact
  • Conflict of Interest Policy

Media

  • Media office
  • News releases

Support Our Work

  • Make a gift today
  • Monthly Giving Circle
  • Ways to Give
  • Guttmacher Guardians
  • Guttmacher Legacy Circle
  • Financials
  • Impact Report 2025

Awards & Scholarships

  • Darroch Award
  • Richards Scholarship
  • Bixby Fellowship
Donate
Guttmacher Institute
Donate

Highlights

  • Reproductive Health Impact Study
  • Adding It Up
  • Abortion Worldwide
  • Guttmacher-Lancet Commission
  • US policy resources
  • State policy resources
  • International Perspectives on Sexual and Reproductive Health (1975–2020)
  • Perspectives on Sexual and Reproductive Health (1969–2020)

Reports

  • Global
  • United States

Articles

  • Global research
  • US research
  • Policy analysis
  • Guttmacher Policy Review
  • Opinion

Fact Sheets

  • Global
  • United States
  • US State Laws and Policies

Tools

  • Interactive Map: US Abortion Policies and Access After Roe
  • Family Planning Investment Impact Calculator
  • Monthly Abortion Provision Study Dashboard
  • State legislation tracker
  • Public-use data sets

Global

  • Abortion
  • Contraception
  • Pregnancy
  • Teens

US

  • Abortion
  • Contraception
  • Pregnancy
  • Teens

Our Work by Geography

  • Global
  • Africa
  • Asia
  • Europe
  • Latin America & the Caribbean
  • Northern America
  • Oceania

Who We Are

  • About
  • Staff
  • Board
  • Job opportunities
  • Newsletter
  • History
  • Contact
  • Conflict of Interest Policy

Media

  • Media office
  • News releases

Support Our Work

  • Make a gift today
  • Monthly Giving Circle
  • Ways to Give
  • Guttmacher Guardians
  • Guttmacher Legacy Circle
  • Financials
  • Impact Report 2025

Awards & Scholarships

  • Darroch Award
  • Richards Scholarship
  • Bixby Fellowship
Donate
  • X
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
  • Contact
Video
February 11, 2025

What happens if the FDA leader ignores science?

Guttmacher explains how FDA leadership impacts access to birth control and medication abortion, warning that abandoning scientific evidence—especially on mifepristone—could drastically restrict abortion access nationwide despite decades of proof of its safety and effectiveness. 

Transcript: What could happen to abortion access in the US if the person leading the FDA abandoned scientific evidence?  

The US Food and Drug Administration is responsible for ensuring that medications and medical devices are safe and effective. This oversight includes many forms of birth control and medication abortion.  

If the FDA were to restrict the abortion pill mifepristone, it would have a significant impact on abortion access across the country, even in states where abortion is legal. For background. Since Roe v. Wade was overturned, medication abortion use has increased in the US. About two-thirds of all US abortions are now medication abortions. And the evidence is clear. Mifepristone is safe and effective and helps to ensure the health and wellbeing of all.  

Anti-abortion groups have already tried to impose medically unnecessary restrictions on mifepristone. Their recent efforts have failed. But a leader of the FDA who opposes abortion could help these groups realize their anti-health, anti-science and anti-rights agenda.  

The bottom line? The leader of the FDA must always prioritize scientific evidence over political agendas. Learn more about how FDA leadership could affect our reproductive rights by heading to the link in our bio or visiting guttmacher.org. 

Share

Guttmacher Institute

Center facts. Shape policy.
Advance sexual and reproductive rights.®

Donate Now
Newsletter Signup  Contact Us 
  • X
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
  • Contact

Footer

  • Privacy Policy
  • Accessibility Statement
© 2025 Guttmacher Institute. The Guttmacher Institute is registered as a 501(c)(3) nonprofit organization under the tax identification number 13-2890727. Contributions are tax deductible to the fullest extent allowable.